Vilon Research: Dipeptide Thymic Bioregulator

Vilon (Lys-Glu) is a synthetic dipeptide bioregulator derived from the thymus gland, developed by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology. As the smallest compound in the Khavinson bioregulator series at just two amino acids (MW 275 Da), Vilon represents the minimal thymic-derived sequence with documented immunomodulatory activity in published research models.

Structural Simplicity and Research Significance

The dipeptide Lys-Glu contains just two residues — a lysine with its positively charged epsilon-amine at physiological pH, and a glutamate with its negatively charged gamma-carboxylate. This ionic complementarity between the two residues enables salt bridge formation that stabilises a compact conformation, and the overall near-neutral net charge at pH 7.4 (Lys +1, Glu -1 = 0) provides reasonable aqueous solubility without the charge-dependent precipitation issues that affect many synthetic peptides.

Vilon's simplicity has important research advantages. As a dipeptide, it can be chemically characterised and confirmed by multiple standard analytical methods — mass spectrometry, NMR, HPLC — with high confidence in structural identity. It has no stereochemical ambiguity in backbone geometry (both residues are L-configuration). And its small size means that essentially all of the molecule is pharmacophore — there are no conformationally flexible linker regions or terminal extensions that complicate structure-activity analysis.

Thymic Biology Context

Vilon was developed in the context of thymic involution research — the age-related progressive loss of thymic cortex and medulla that produces dramatically reduced naive T cell output by the fifth decade of life. The thymus is the exclusive site of T lymphocyte maturation from haematopoietic progenitors, and its involution produces the adaptive immune contraction characteristic of immunosenescence.

The thymulin bioassay provides the primary functional endpoint for thymic epithelial biology research relevant to Vilon. Thymulin (Facteur Thymique Sérique) is a zinc-requiring nonapeptide hormone produced exclusively by thymic epithelial cells. Its plasma concentration declines with age in parallel with thymic involution, and it is proposed to drive T cell maturation in the thymic cortex. Measuring thymulin production by thymic epithelial cell cultures treated with Vilon provides direct insight into bioregulator effects on thymic endocrine function.

Immunological Research Applications

T cell proliferation in aged models: Splenocytes from aged rodents (18-24 months) show measurably reduced proliferative responses to T cell mitogens compared to young adults (2-4 months) — reflecting the reduced naive T cell pool and altered T cell subset composition that accompanies immunosenescence. Vilon treatment (1nM-100µM range, testing broad concentration range for dipeptides) of aged splenocyte cultures before mitogenic stimulation (concanavalin A 2.5µg/mL or anti-CD3/CD28 antibodies) allows assessment of proliferative restoration. Measure by [3H]-thymidine incorporation (last 18 hours of 72-hour culture) or CFSE dilution by flow cytometry.

Cytokine profiling: Measure IL-2 (24 hours, the primary autocrine T cell proliferation cytokine), IL-4 and IL-13 (Th2 markers), IFN-gamma (Th1 marker), and IL-17 (Th17 marker) in supernatants from Vilon-treated stimulated T cell cultures. The Th1/Th2/Th17 balance provides mechanistic insight into whether Vilon preferentially supports specific T cell subset responses.

NK cell function: Natural killer cell cytotoxicity against K562 targets (which lack MHC I and are therefore sensitive to NK killing) provides a GHS-independent innate immune endpoint. Enrich NK cells from splenocyte preparations by negative selection. Pre-treat with Vilon for 24 hours. Perform 4-hour 51Cr release assay at multiple effector:target ratios.

Comparative Bioregulator Research

The most informative Vilon research design places it within the context of the full thymic bioregulator series. Running Vilon (dipeptide, 275 Da), Thymalin (polypeptide, 1400-1500 Da), and Thymosin Alpha-1 (defined 28 amino acid peptide, 3108 Da) in parallel immunological assays at matched mass concentrations (µg/mL) and separately at matched molar concentrations (nM) provides complementary information. Mass-matched comparison reflects clinical dosing conventions; molar-matched comparison reflects receptor pharmacology conventions. The two comparisons together characterise whether potency differences are attributable to molecular weight or to intrinsic activity at the relevant receptors.

Key Published Research

• Morozov VG, Khavinson VKh. "Natural and synthetic thymic peptides as therapeutics for immune dysfunction." International Journal of Immunopharmacology, 1997. PMID: 9088759
• Khavinson VK, et al. "Peptide regulation of ageing." St. Petersburg: Humanistics, 2003.
• Anisimov SV, et al. "Effect of the synthetic thymic dipeptide Vilon and melatonin on gene expression in lymphocytes of old mice." Advances in Gerontology, 2004.

View Vilon →

For laboratory and analytical research purposes only. Not for human or veterinary use.